Patents by Inventor Liuhong Chen
Liuhong Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11542304Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: GrantFiled: October 26, 2020Date of Patent: January 3, 2023Inventors: Liuhong Chen, Rachid Lani, Kevin Mcdonnell, Gemma Mudd, Peter U. Park, Punit Upadhyaya
-
Publication number: 20220363718Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of thymic stromal lymphopoietin (TSLP). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder mediated by TSLP.Type: ApplicationFiled: April 6, 2021Publication date: November 17, 2022Inventors: Frank NARJES, Tor SVENSSON, Pavol ZLATOIDSKY, Lotta HIDESTAL, Liuhong CHEN, Michael SKYNNER, Sophie WATCHAM
-
Patent number: 11484602Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: December 14, 2018Date of Patent: November 1, 2022Assignee: BicycleTx LimitedInventors: Liuhong Chen, Philip Huxley, Silvia Pavan, Katerine Van Rietschoten
-
Publication number: 20220306689Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.Type: ApplicationFiled: December 23, 2019Publication date: September 29, 2022Inventors: Liuhong CHEN, James COOKE, Kevin MCDONNELL, Gemma MUDD, Katerine VAN RIETSCHOTEN, Punit UPADHYAYA
-
Patent number: 11453702Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: GrantFiled: September 30, 2021Date of Patent: September 27, 2022Assignee: BICYCLETX LIMITEDInventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
-
Publication number: 20220296726Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TREM2. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder mediated by TREM2.Type: ApplicationFiled: March 18, 2022Publication date: September 22, 2022Applicant: BicycleTx LimitedInventors: Paul Brennan, Amy Brown, Liuhong Chen, John Davis, Yuliya Demydchuk, Donatella Di Rienzo, Ellen Gowans, Rama McCrory, Emma Mead, Emma Murphy, Mike Rigby, Michael Skynner, Tom Smith, Steven Stanway
-
Publication number: 20220289792Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: ApplicationFiled: December 19, 2018Publication date: September 15, 2022Inventors: Liuhong CHEN, Philip HUXLEY, Silvia PAVAN, Katerine VAN RIETSCHOTEN
-
Publication number: 20220281918Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.Type: ApplicationFiled: August 28, 2020Publication date: September 8, 2022Inventors: Katerine VAN RIETSCHOTEN, Paul BESWICK, Mike DAWSON, Matthew BALMFORTH, Michael SKYNNER, Liuhong CHEN
-
Publication number: 20220213145Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: ApplicationFiled: January 21, 2022Publication date: July 7, 2022Inventors: Liuhong CHEN, Rachid LANI, Kevin MCDONNELL, Gemma Elizabeth MUDD, Peter PARK
-
Publication number: 20220133732Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of carbonic anhydrase IX (CAIX).The invention also includes dmg conjugates comprising said peptides,conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CAIX.Type: ApplicationFiled: January 15, 2020Publication date: May 5, 2022Inventors: Leonardo BALDASSARRE, Liuhong CHEN, Rachid LANI, Catherine STACE, Daniel TEUFEL, Edward WALKER
-
Publication number: 20220088207Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.Type: ApplicationFiled: December 23, 2019Publication date: March 24, 2022Inventors: Liuhong CHEN, James COOKE, Kevin MCDONNELL, Gemma MUDD, Katerine VAN RIETSCHOTEN, Punit UPADHYAYA
-
Publication number: 20220088118Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of carbonic anhydrase IX (CAIX). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CAIX.Type: ApplicationFiled: January 15, 2020Publication date: March 24, 2022Inventors: Leonardo BALDASSARRE, Liuhong CHEN, Rachid LANI, Catherine STACE, Daniel TEUFEL, Edward WALKER
-
Publication number: 20220089643Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: ApplicationFiled: September 30, 2021Publication date: March 24, 2022Inventors: Paul BESWICK, Liuhong CHEN, Gemma MUDD, Peter PARK, Katerine VAN RIETSCHOTEN, Michael RIGBY
-
Patent number: 11261214Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: GrantFiled: August 3, 2018Date of Patent: March 1, 2022Assignee: BicycleTx LimitedInventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Mudd, Peter Park
-
Publication number: 20220054646Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of prostrate-specific membrane antigen (PSMA).The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PSMA.Type: ApplicationFiled: December 13, 2019Publication date: February 24, 2022Inventors: Liuhong CHEN, Catherine STACE, Daniel TEUFEL, Punit UPADHYAYA, Edward WALKER
-
Publication number: 20220024983Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of IL-17. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by IL-17.Type: ApplicationFiled: December 13, 2019Publication date: January 27, 2022Inventors: Liuhong CHEN, Rachid LANI, Gemma MUDD, Daniel TEUFEL, Edward WALKER
-
Publication number: 20220024982Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.Type: ApplicationFiled: December 13, 2019Publication date: January 27, 2022Inventors: Liuhong CHEN, Euan RICHARDS, Rachid LANI, Gemma MUDD, Catherine STACE, Daniel TEUFEL, Edward WALKER
-
Publication number: 20220008545Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of fibroblast activation protein a (FAP?). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by FAP?.Type: ApplicationFiled: December 13, 2019Publication date: January 13, 2022Inventors: Liuhong CHEN, Catherine STACE, Edward WALKER
-
Patent number: 11180531Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: GrantFiled: June 20, 2019Date of Patent: November 23, 2021Assignee: BicycleTx LimitedInventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
-
Publication number: 20210269480Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4.The invention also includes drug conjugates comprising said peptides,conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: ApplicationFiled: June 21, 2019Publication date: September 2, 2021Inventors: Paul BESWICK, Liuhong CHEN, Gemma Elizabeth MUDD, Peter PARK, Katerine VAN RIETSCHOTEN, Michael RIGBY